Approval pits Novartis meningococcal vaccine against Pfizer shot

Physicians now have a second serogroup B meningococcal vaccine in their arsenal. The FDA approved Novartis's Bexsero this past weekend after greenlighting Pfizer's Trumemba just three months ago, in October. Meningococcal disease is typically treated with antibiotics to minimize risk of death and other serious long-term problems. The FDA says that vaccination is now the most effective way to prevent meningococcal disease. The agency had granted Bexsero Breakthrough Therapy Designation.


Next Article in Pharmaceutical